CCM
CORT icon

Cadence Capital Management’s Corcept Therapeutics CORT Stock Holding History

Cadence Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-145,133
Closed -$1.71M – 676
2017
Q2 		$1.71M Buy
145,133
+72,464
+100% +$788K 0.12% 203
2017
Q1 		$796K Sell
72,669
-33,054
-31% -$290K 0.05% 404
2016
Q4 		$768K Sell
105,723
-43,676
-29% -$342K 0.05% 410
2016
Q3 		$971K Buy
149,399
+78,491
+111% +$456K 0.07% 319
2016
Q2 		$387K Buy
+70,908
New +$369K 0.03% 490

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cadence Capital Management's CORT Position: Q3 2017 in Review

Cadence Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2017, closing a stake of 145,133 shares — an estimated $1.71M sold.

Cadence Capital Management first reported a position in CORT in Q2 2016 and held it in 5 quarters. The position peaked at $1.71M in Q2 2017. 189 funds tracked by Wall St. Rank hold CORT as of Q3 2017.

  • Cadence Capital Management reported no remaining Corcept Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Cadence Capital Management sold 145,133 Corcept Therapeutics shares in Q3 2017, an estimated $1.71M.
  • Cadence Capital Management first reported a position in Corcept Therapeutics in Q2 2016 and held it in 5 quarters.
  • Cadence Capital Management's Corcept Therapeutics position peaked at $1.71M in Q2 2017.
  • 189 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2017.

Based on Cadence Capital Management's 13F filing for Q3 2017, filed 9 Nov 2017.